Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reducing delays in radiotherapy initiation post CT simulation: a quality improvement study from a rural cancer center in India.

Ecancermedicalscience·2026

Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026

Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026

Same author

A prospective observational study to assess the compliance to enhanced recovery protocols among patients undergoing bone and soft tissue cancer surgeries and their postoperative outcomes.

Indian journal of surgical oncology·2026

Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Search research articles

Related Experiment Video

Updated: Jun 5, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Advancing Systemic Therapy in Chondrosarcoma: New Horizons.

Ka Hou C Li^1,2, Ashish Gulia³, Florence Duffaud⁴

¹Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UK.

Oncology and Therapy

|December 9, 2024

Summary

This summary is machine-generated.

Systemic treatment for advanced chondrosarcoma is challenging. New therapies targeting isocitrate dehydrogenase (IDH) mutations, signaling pathways, and immune modulation show promise, especially in combination approaches.

Keywords:

Advanced/metastatic chondrosarcoma DR5 agonist IDH inhibitors Immunotherapy Systemic therapy

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Related Experiment Videos

Last Updated: Jun 5, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Area of Science:

Oncology
Medical Genetics
Pharmacology

Background:

Advanced and metastatic chondrosarcoma presents significant treatment challenges due to limited responsiveness to conventional therapies.
Certain subtypes like mesenchymal and dedifferentiated chondrosarcomas show initial response to therapies developed for other sarcomas.

Purpose of the Study:

To review current and investigational systemic treatment strategies for advanced chondrosarcoma.
To highlight emerging molecular targets and combination therapy approaches for improved patient outcomes.

Main Methods:

Review of preclinical and clinical data on targeted therapies including IDH inhibitors, hedgehog pathway inhibitors, and immunotherapy.
Evaluation of novel agents like DR5 agonists (e.g., INBRX-109) and their potential in combination regimens.
Emphasis on multi-omics and genetic profiling for personalized treatment strategies.

Main Results:

IDH inhibitors show promise in early trials for chondrosarcoma with IDH mutations.
Hedgehog pathway inhibitors have yielded mixed clinical results.
DR5 agonists demonstrate single-agent efficacy with low toxicity, suggesting potential for combination therapy.
Immunotherapy faces challenges due to the tumor microenvironment but remains an area of investigation.

Conclusions:

Personalized, combination therapies targeting multiple carcinogenic pathways are crucial for overcoming chondrosarcoma heterogeneity and resistance.
Integrating IDH inhibitors, immunotherapy, and DR5 agonists offers a hopeful direction for transforming advanced chondrosarcoma management.